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Summary  Myocardial  infarction  (MI)  in  pregnant  patients  confer  additional  risks  and  unique
problems  related  to  necessity  of  concomitant  obstetric  interventions  and  coexistence  of  disor-
ders  as  hypercoagulability.  Therefore,  patients  usually  have  a  more  complicated  course  which
demands  prompt  diagnosis  and  appropriate  treatment.  Here  we  report  a  22  year  old  pregnant
woman  with  an  acute  anterior  myocardial  infarction  and  the  complicated  course  of  the  man-
agement.  Although  the  patient  underwent  a  successful  percutaneous  coronary  intervention  atBleeding
complications
the  ﬁrst  presentation  with  MI,  one  week  later  she  suffered  a  stent  thrombosis  presumably  due
to  cessation  of  clopidogrel  in  order  to  prevent  bleeding  before  the  termination  of  pregnancy.
Later,  a  detailed  examination  of  the  patient  has  led  to  diagnosis  of  antiphospholipid  antibody
syndrome.
©  2011  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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cute  coronary  syndromes  in  pregnant  patients  confer
dditional risks  and  unique  problem  associated  with,  limita-
ions of  management  alternatives,  necessity  of  concomitant
bstetric interventions  and  coexistence  of  disorders  as
ntiphospholipid antibody  syndrome.  The  antiphospholipid
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oi:10.1016/j.jccase.2011.04.006ntibody  syndrome  (APAS),  a  systemic  autoimmune  disease
haracterized by  recurrent  arterial  and  venous  thrombo-
is and/or  pregnancy  loss  in  association  with  circulating
ntiphospholipid antibody,  is  the  most  common  acquired
hrombophilia. The  incidence  of  antiphospholipid  antibody
yndrome is  2—4%  [1—3]  in  general  population  and  its  usually
ssociated with  in  venous  thrombophilia  [4,5]  and  systemic
upus erythematosus  (30%)  [6].  Coronary  thrombosis  as  a
anifestation of  the  antiphospholipid  antibody  syndrome  is
ccasionally rare.  The  cardiac  manifestations  of  this  disease
nclude valvular  abnormalities  (thrombotic  vegetations  or
hickening), myocardial  infarction,  intracardiac  thrombi  and
yocardial microthrombosis.
 Published by Elsevier Ltd. All rights reserved.
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Figure  1  Twelve-lead  electrocardiography  during  chest  pain  showing  ST  segment  elevation  in  leads  I,  aVL,  V1—V6,  and  reciprocal
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TST  segment  depression  in  leads  II,  III,  and  aVF.
Here  in,  we  report  the  complicated  course  and
management of  an  acute  myocardial  infarction  due  to
antiphospholipid antibody  syndrome  in  a  pregnant  patient.
Case report
Twenty  two  year-old,  twelve  week  pregnant  woman  was
admitted with  retrosternal  chest  pain  radiating  to  left
arm with  a  duration  of  12  h.  Her  past  medical  history
was unrelevant  except  one  spontaneous  abortus  2  years
ago and  a  family  history  for  coronary  artery  disease.
Her physical  examination  revealed  a  blood  pressure  of
112/78 mmHg,  and  a  pulse  rate  of  81  min.  Auscultatory  ﬁnd-
ings were  normal  except  the  presence  of  S4.  Twelve-lead
electrocardiography  recorded  during  chest  pain  showed  ST
segment elevation  in  leads  I,  aVL,  V1—V6  and  reciprocal
ST segment  depression  in  leads  II,  III  and  aVF  (Fig.  1).
The initial  laboratory  ﬁndings  at  admission  were  as  fol-
lows: CK:  3151  U/L,  CK-MB:  474  U/L,  Troponin:  >100  ng/mL
and echocardiography  showed  anteroapical,  anterosep-
tal akinesia  and  midseptal  hypokinesia  with  an  ejection
fraction of  35—40%.  The  patient  was  transferred  to  the
catheterization laboratory  immediately  with  an  intention
for primary  percutaneous  coronary  intervention  (PCI).  Three
hundred milligrams  acetylsalicylic  acid  with  600  mg  loading
dose clopidogrel  was  orally  administered  and  0.75  mg/kg
intravenous enoxaparine  was  given  before  procedure.  An
immediate  coronary  angiography  showed  a  subtotal  occlu-
sion of  mid  left  anterior  descending  artery  (LAD)  (Fig.  2A).
The circumﬂex  and  right  coronary  arteries  were  disease
free. The  lesion  was  dilated  with  a  balloon.  Although  the
h
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lnitial  strategy  was  balloon  recanalization  only  in  order  to
void stent  implantation  which  will  lead  to  necessity  of  long
erm  clopidogrel  use.  However,  the  distal  perfusion  of  the
essel was  suboptimal  after  balloon  recanalization,  there-
ore 3.5  × 16 mm  bare  metal  stent  was  implanted  with  18
tmosphere (Fig.  2B).  A  slow  ﬂow  was  observed  in  LAD
ollowing stent  implantation  and  the  ﬂow  was  restored
fter administration  of  1  mg  (0.5  +  0.5  mg)  of  intracoro-
ary verapamil.  Finally,  TIMI  III  ﬂow  was  established,  pain
as relieved  and  complete  ST  resolution  was  observed  in
nterior derivations.  The  transthoracic  echocardiography
howed left  ventricular  apical  dyskinesis,  and  aneursym
ormation with  a  trombus  inside.  The  ejection  fraction
as 20%.  The  patient  stayed  in  cardiology  department  for
 days  and  then  referred  to  obstetrics  department  for
ermination of  pregnancy  in  accordance  with  the  obstetri-
ians suggestions.  Clopidogrel  was  stopped  5  days  prior  to
bortion, aspirin  continued  and  subcutaneous  enoxaparine
as started.  Termination  of  pregnancy  was  performed  with
otassium hydrochloride  injection  to  fetal  heart  and  no
leeding complication  was  seen  during  the  procedure.
wo days  after  the  abortus  the  patient  has  experienced
hest pain  resembling  the  previous  event.  Therefore  the
atient was  transferred  to  catheterization  laboratory  for
mmediate PCI  with  a  diagnosis  of  presumed  stent  throm-
osis due  to  discontinuation  of  clopidogrel.  Angiography
howed a totally  occluded  LAD  due  to  stent  thrombosis.
iroﬁban infusion  was  started,  10,000  units  of  unfractional
eparin, 300  mg  acetylsalicylic  acid  and  600  mg  clopido-
rel was  administered  immediately.  The  stent  was  crossed
ith a  soft  wire  and  several  thrombus  aspirations  and  bal-
oon dilatation  were  performed.  Unfortunately  thrombus
e10  
Figure  2  (A)  The  coronary  angiography  showed  a  subto-
tal occlusion  of  mid  left  anterior  descending  artery.  (B)  The
coronary angiography  showed  3.5  × 16 mm  bare  metal  stent
implantation at  18  atmospheres  to  the  mid  left  anterior
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aescending artery  for  suboptimal  distal  perfusion  of  the  vessel
ollowing balloon  recanalization.
spirations  and  balloon  recanalization  attempts  failed  and
ll recanalizations  were  followed  by  reocclusion  due  to
eavy thrombus  burden.  As  a  last  attempt  250.000  units
f streptokinase  was  infused  with  an  infusion  catheter
nto the  LAD  selectively  for  3  min.  Intracoronary  throm-
olytic infusion  also  failed.  During  her  coronary  care  unit
ollow up  she  developed  complete  atrioventricular  block
hich responded  intravenous  atropine  administration.  The
ontrol echocardiography  revealed  an  ejection  fraction  of
0% with  an  aneursymatic  left  ventricle  with  thrombus.
wo days  later  curettage  was  performed  due  to  incom-
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lete  abortion.  Rheumatologic  and  hematologic  tests  were
s  follows:  free  T3  (sT3):  2.74  pg/mL  (1.8—4.2),  free  T4
sT4): 1.06  ng/dL  (0.7—1.9),  thyroid-stimulating  hormone
TSH): 14.06  mIU/L  (0.4—4.20),  anti-thyroid  peroxidase
utoantibody (TPO):  3.04  IU/mL  (0—35),  anti-thyroglobulin
TG): 3.45  IU/mL  (0—40),  low  density  lipoprotein  (LDL):
16 mg/dL,  triglyceride  (TG):  152  mg/dL,  high  density
ipoprotein (HDL):  43  mg/dL,  HbA1C:  6.9%,  compleman  3C
C3C): 1.44  g/L  (0.9—1.8),  compleman  4C  (C4C):  0.55  g/L
0.1—0.4), protein  C:  131%  (70—140%),  protein  S:  44%
60—123%), anti-thrombin  III  activity:  103.1%  (75—125%),
omocysteine: 11.7  mol/L  (0—15  mol/L),  anti-Sjogren
yndrome A  (SSA):  0.277  (<1),  anti-Sjogren  Syndrome
 (SSB):  0.321  (<1),  beta-2  glycoprotein  IgM:  116  (>20
ositive), beta-2  glycoprotein  IgG:  <2.0  (>20  positive),
nti-cardiolipin IgM:  3.545  MPLU/mL  (0—7  MPLU/mL),  anti-
ardiolipin IgG:  7.089  GPLU/mL  (0—10  GPLU/mL),  lupus
nticoagulant: medium  positive,  antinuclear  antibody
ANA): strong  positive,  anti-double  strand  DNA(ds-DNA):
.28 (>1.1  positive).  Levothyroxine  50  mcg  was  started  for
er subclinical  hypothyroidia.  She  was  given  systemic  lupus
rythematosus prophylaxis  with  hydroxychlorochine  and
arfarin was  administered  with  the  indication  of  antiphos-
holipid antibody  syndrome  with  left  ventricular  thrombus.
fter achieving  target  INR  values,  she  was  discharged  and
eferred to  rheumatology  and  cardiology  outpatient  clinics
or further  follow-up.
iscussion
cute  myocardial  infarction  (AMI),  which  carries  a  high  risk
f maternal  and  perinatal  mortality,  complicates  approxi-
ately 1  in  10,000  pregnancy.  Although  patients  presenting
ith AMI  during  pregnancy  tend  to  be  younger  and  have
ess co-morbidities,  the  maternal  mortality  from  AMI  is  high
p to  21%  [7].  Identiﬁed  risk  factors  for  coronary  artery
isease in  young  women  include  diabetes  mellitus,  smok-
ng, dyslipidemia,  family  history,  and  previous  use  of  oral
ontraceptives [8].  The  underlying  precipitating  factors  of
MI in  pregnancy  are  thought  to  be  multifactorial  and
ttributable to  the  physiological  events  that  occur  during
regnancy. The  increased  myocardial  oxygen  demand  due
o marked  increases  in  blood  volume,  stroke  volume,  and
eart rate,  profound  alterations  in  the  coagulation  and  ﬁb-
inolytic system  that  lead  to  increased  risk  of  thrombosis,
he physiological  anemia  and  decreased  diastolic  blood  pres-
ure that  may  reduce  myocardial  oxygen  supply  are  the
ost important  mechanisms  leading  to  AMI  in  peripartal
omen [9].  In  contrast  to  the  general  population,  under-
ying atherosclerotic  disease  is  documented  in  less  than
alf (43%)  [8]  of  the  acute  coronary  syndrome  cases  seen
n pregnant  patients.  Normal  coronary  arteries  were  found
n 29%  [8]  of  reported  cases  in  which  the  coronary  artery
natomy was  deﬁned.  In  general  terms  it  appears  that  preg-
ant women  are  at  3—4  times  greater  risk  of  AMI  than  age
atched non-pregnant  women,  although  the  incidence  in
bsolute terms  is  very  small.  Independent  predisposing  fac-
ors that  have  been  associated  with  an  increased  risk  of
nfarction in  a  pregnant  women  are  age  over  30  years,  third
rimester of  pregnancy,  multiparity,  hypertension,  eclamp-
ia, pre-eclampsia,  diabetes,  smoking,  thrombophilia,  need
y  sy
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for  blood  transfusion,  and  appearance  of  infection  follow-
ing delivery  [9].  Non-atherosclerotic  etiologies  likely  to  be
responsible from  MI  in  pregnant  patients  include  throm-
bosis, coronary  artery  spasm,  spontaneous  coronary  artery
dissection, collagen  vascular  disease,  aortic  valvular  steno-
sis, prosthetic  valve  thrombosis,  sickle  cell  disease,  and
thrombophilic disorders  like  antiphospholipid  syndrome  as
in our  case  [9].  The  pathogenic  mechanisms  of  the  antiphos-
pholipid antibody  syndrome  that  lead  to  in  vivo  injury  and
vessel thrombosis  are  unknown.  APAS  are  found  in  15—30%  of
patients presenting  with  venous  thromboembolism  [4,5],  in
about 25%  of  patients  presenting  with  ﬁrst  ischemic  stroke
[10], and  in  approximately  2.8%  of  young  people  present-
ing with  ﬁrst  myocardial  infarction  [11].  Their  prevalence  in
the unselected  population  is  unknown.  About  30%  of  indi-
viduals with  systemic  lupus  erythematosus  have  an  APAS
[12]. Myocardial  infarction  (MI)  in  pregnant  patients  confer
additional risks  and  unique  problems  related  to  necessity
of concomitant  obstetric  interventions  and  coexistence  of
disorders as  hypercoagulability.  The  most  important  points
relevant to  the  management  of  patients  with  AMI  during
pregnancy are  the  timing  of  the  delivery  and  drug  treat-
ment. A  number  of  cases  reporting  successful  PCI  as  a
treatment of  STEMI  during  pregnancy  have  been  published
[13,14]. Evidence-based  treatment  of  these  patients  is  dif-
ﬁcult due  to  the  lack  of  data  from  randomized  controlled
trials. Trombolysis  agents  are  not  recommended  due  to
risk of  hemorrhagic  complications  as  spontaneous  abor-
tion, minor  vaginal  bleeding,  spontaneous  hematoma  in  the
inguinal and  axillary  region  requiring  blood  transfusion,  fatal
abruptio with  fetal  death,  uterine  bleeding  necessitating
emergency cesarean  section,  and  postpartum  hemorrhage
requiring transfusion.  The  optimal  management  approach
for NSTEMI  or  USAP  have  also  not  yet  been  deﬁned.  In  the
presence of  ongoing  myocardial  ischemia,  the  recommen-
dations are  to  administer  aspirin,  unfractionated  heparin,
B-blockers, and  nitroglycerin,  and  to  perform  immediate
coronary angiography.  Depending  on  the  patient’s  coronary
anatomy and  response  to  medical  management,  therapy
options range  from  a  conservative  approach  to  percutaneous
coronary intervention  or  coronary  artery  bypass  surgery.
Since percutaneous  and  surgical  revascularizations  may  be
very challenging  in  the  setting  of  pregnancy,  medical  man-
agement should  be  considered  as  the  ﬁrst  line  treatment  in
the absence  of  ongoing  ischemia.  It  is  best  to  avoid  stent
implantation and  rather  prefer  plain  balloon  angioplasty  in
these patients  because  of  the  detrimental  effects  of  clopido-
grel discontinuation  for  abortus  or  delivery.  In  case  of  stent
implantation, as  in  our  experience,  cessation  of  clopidogrel
may cause  catastrophic  outcomes  [9].  Therefore,  in  patients
who underwent  percutaneous  coronary  interventions  and
stenting, clopidogrel  could  be  discontinued  only  in  the  pres-
ence of  compelling  contraindications  to  antiplatelet  agents.
An alternative  strategy  can  be  switching  from  clopidogrel  5
days before  surgery  to  a  reversible  antiplatelet  agent  with
a short  half-life  as  a  glycoprotein  IIb/IIIa  or  eptiﬁbatide  and
stopping the  infusion  4  h  before  the  surgery  or  abortion.  Fol-
lowing the  surgery,  resumption  of  clopidogrel  as  soon  as
possible after  the  establishment  of  hemostasis  is  strongly
recommended. The  substitution  of  dual  antiplatelet  treat-
ment with  low  molecular  weight  heparin  or  unfractionated
heparin is  not  effective.  In  other  scenarios  which  necessitate
[ndrome  in  a  young  pregnant  woman  e11
ong  term  anticoagulation  as  presence  of  atrium  ﬁbrilla-
ion or  prosthetic  valves,  unfractionated  heparin  (UFH)  and
ow molecular  weight  heparin  (LMWH)  are  considered  as
he anticoagulation  of  choice  during  pregnancy  because
heir large  molecular  weights  prevent  them  from  crossing
he placenta  and  therefore  precludes  teratogenic  effects.
he safety  of  higher  doses  of  aspirin  and  aspirin  ingestion
uring the  ﬁrst  trimester  remains  uncertain.  The  use  of
ewer antiplatelet  agents  during  pregnancy,  such  as  gly-
oprotein IIb/IIIa  antagonists,  ticlopidine,  and  clopidogrel
ave been  reported  in  the  literature;  however,  very  little
ata exist  for  their  use  in  management  of  pregnant  patients
9].
In conclusion,  despite  a  prompt  and  appropriate  diagnosis
nd management,  acute  MI  in  pregnant  patients  who  have
ntiphospholipid antibody  syndrome  may  follow  a  compli-
ated course  and  lead  to  a  poor  outcome.  Therefore  optimal
reatment strategy  for  this  situation  requires  further  inves-
igation.
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